NCT05558319: Phase 3: (GEM21menos65) Extended VRD Plus vs Isa-VRD vs Isa-V-Iberdomide - NDMM - ASCT
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant
NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6
NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
NCT05338047: Phase 2: Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery ASCT
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
NCT05346809: Phase 2: Isatuximab During Stem Cell Collection and Transplant in Myeloma & Lymphoma
NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation
NCT05354557: Phase 2 - Study of Iberdomide in Multiple Myeloma Post ASCT Transplant
NCT04934475: Phase 3 - IFM 2020-02 Minimal Residual Disease Adapted Strategy (MIDAS) KRD-Isatuximab
NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma
NCT04680468: Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant & Maintenance
NCT04564703: EMN26 Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial
NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma
NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC
NCT04108624: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for ASCT in Myeloma (CarMob)
NCT03562169: Phase 3: Ixazomib in Autologous Stem Cell Transplant in RRMM Myeloma XII (ACCoRd)